LGALS1 and neoplasm: Moreover, in lymphoma, galectin-1 expression is strongly correlated with resistance to immunotherapy; in fact, galectin-1-overexpressing lymphoma cells blunt antibody-dependent tumor phagocytosis in vitro, and, in vivo, galectin-1 reduces lymphoma cells sensitivity to CD20 immunotherapy [20].